Addex Therapeutics reported a net profit of CHF 9.8 million for H1 2024, primarily due to the Neurosterix Transaction. Revenue decreased to CHF 0.3 million from CHF 1.1 million in H1 2023, reflecting lower income from the Indivior collaboration.R&D and G&A expenses remained stable at CHF 0.6 million and CHF 1.5 million respectively. The company received CHF 5.0 million cash and a 20% stake in Neurosterix from divesting its discovery platform and early-stage programs. Addex retains key partnerships and clinical-stage assets including dipraglurant.Cash and equivalents stood at CHF 3.8 million as of June 30, 2024. Management expects current funds to support operations through 2026. Addex plans to advance its GABAB PAM program for chronic cough and explore partnering opportunities for dipraglurant in post-stroke/TBI recovery.

Addex Therapeutics reported a net profit of CHF 9.8 million for H1 2024, primarily due to the Neurosterix Transaction. Revenue decreased to CHF 0.3 million from CHF 1.1 million in H1 2023, reflecting lower income from the Indivior collaboration.R&D and G&A expenses remained stable at CHF 0.6 million and CHF 1.5 million respectively. The company received CHF 5.0 million cash and a 20% stake in Neurosterix from divesting its discovery platform and early-stage programs. Addex retains key partnerships and clinical-stage assets including dipraglurant.Cash and equivalents stood at CHF 3.8 million as of June 30, 2024. Management expects current funds to support operations through 2026. Addex plans to advance its GABAB PAM program for chronic cough and explore partnering opportunities for dipraglurant in post-stroke/TBI recovery.